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A. Borderline Resectable PDAC

Pancreatic cancer has shown little improvement in the 5-year survival
rate since the 1970s (Rawla et. al. 2019)

CA19-9 is the most widely used biomarker for pancreatic cancer
(Kleeff et. al. 2016)

B. Locally Advanced PDAC

Normalization of CA19-9, defined as levels < 40 U/mL, is associated
with improved prognosis (Tzeng et. al. 2014)
We aimed to identify the trends of CA19-9 levels in patients with
pancreatic cancer undergoing chemotherapy and develop a
mathematical model that predicts outcomes to enhance treatment
protocol.

Methods

C. Resectable PDAC
Fig 2. CA19-9 Normalization by Baseline Levels: Baseline CA19-9
levels were evaluated with respect to eventual normalization and nonnormalization. Normalizers had a lower baseline CA19-9 (median
148.55 U/mL [range 43.6-1562]) compared to non-normalizers
(median 600.8 U/mL [range 53.2-8815], ANOVA, p=0.0016).
A. ROC Curve for Model Prediction of CA19-9 and
Ground Truth for Normalization

• CA19-9 data was collected from 732 patients.
• Patients were selected for modeling if they met the following
criteria (Table 1):
•
•
•
•
•

Baseline CA19-9 level above normalization (40 U/mL)
Normal bilirubin prior to therapy(<2.0 mg/dL)
No metastasis
Uninterrupted FOLFIRINOX or Gemcitabine/Abraxene for 6 months
2+ CA19-9 measurements in addition to baseline

• CA19-9 data were fit to a Type A (“A”lways decreasing) or Type
B (“B”idirectional) exponential decay model (Fig. 1)

Fig 3. CA19-9 Normalization by Disease Class: Proportions
of patients that normalized in each disease class were
assessed with Likelihood Ratios to determine if type of
PDAC affects CA19-9 normalization. 11 of 26 patients with
BR PDAC (A) normalized (p =0.4316). 13 of 46 patients
with LA PDAC (B) normalized (p=.0027). 10 of 14 patients
with Resectable PDAC (C) normalized (p=.1031).

Patient Demographics

Acknowledgements

A. OS for GT Normalizers vs Non-normalizers

B. Model Prediction for Normalization vs
Ground Truth
B. OS for Model Normalizers vs Non-normalizers

• Y[t]=α*exp(β[t])
• Y(t): CA19-9 level at time t
• T(0): Chemotherapy start date
• Α and β: Model parameters describing the shape of the response curve

• Model efficacy was compared to the “Ground Truth” (GT)
presence or absence of CA19-9 normalization within 0-6 months
• ROC and Kaplan-Meier curves assessed model results
• Outcomes and patient trends were analyzed with Likelihood Ratio,
Log Rank, and AUC tests

• The model performed well
in predicting normalization
for a small subset of
patients but requires further
refinement for enhanced
prognostic capabilities and
applications to more diverse
patient profiles and CA19-9
response patterns.
• Ongoing work will examine
additional parameters, test
statistical models, and
approach methods to
account for continuous
elevation of CA19-9.

Fig 4. Assessment of Model Accuracy: An ROC curve (A) for
normalization of CA19-9 from the model’s prediction within 6
months was generated to analyze model performance (AUC =
.866). 73 of the 86 total patients had model results matching
the GT presence or absence of normalization (B).

Fig 5. Kaplan-Meier Curves for GT and Model OS: Overall survival in
days from the start of chemotherapy was plotted for normalizers and
non-normalizers using GT and model responses. GT normalizers (A) had
a median OS of 1037 days compared to 544 days for non-normalizers
(Log rank, p= .0115). Model normalizers (B) had a median OS of 870
days compared to 611 days for non-normalizers (Log-rank, p=0.2441)
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Model Misclassification Shapes

Table 1. Patient Demographics: 86 patients met the criteria for inclusion. Patient counts are provided for normalizers and nonnormalizers; categorized by sex, median age, type of chemotherapy, and type of PDAC.

(A)

Type A: Always Decreasing Trend

(B)

Type B: Bidirectional Trend

Fig 1. CA19-9 Prediction Model Design: Patients with CA19-9 levels decreasing during the initial period (t; 0-60) were fit
to the Type A model (A). Patients with an increase in CA9-9 during the initial period followed by a decrease after T
months were fit to the Type B model (B). Type B is a piece-wise defined curve where its first component has an
increasing trend and the second has a decreasing trend of equal magnitudes with the turning point of f(t) as t=T.

Fig 6. Visualization of Model Misclassification Shapes: 5 patients were misclassified as normalizers by the model: 2 demonstrated a “Ushaped” change in CA19-9 (A) and 3 decreased without normalization (B). 8 patients were misclassified as non-normalizers by the
model: 7 demonstrated a “bidirectional to normalization” change in CA19-9 (C) and 1 demonstrated an inconsistent rate of decline (D).

• Normalizers displayed significantly lower baseline CA19-9 levels (p=.0016) compared to non
normalizers (Fig. 2)
• Patients with LA PDAC are less likely to normalize (Likelihood Ratio, p=.0027) compared to
patients with BR or Resectable PDAC (p > .05) (Fig. 3)
• Application of the model to predict CA19-9 normalization during 6 months of chemotherapy
treatment accurately characterized 73 patients (AUC= .866) (Fig. 4)
• Although both the GT and model responses demonstrated longer median OS for normalizers
compared to non-normalizers, the difference was only statistically significant for the GT
patients (Log rank, p = .0115) (Fig. 5)
• Analysis of misclassifiers showed specific response patterns associated with the inaccurate
model prediction (Fig. 6)

1) Rawla, Prashanth et al. “Epidemiology of
Pancreatic Cancer: Global Trends, Etiology and
Risk Factors.” World journal of oncology vol. 10,1
(2019): 10-27. doi:10.14740/wjon1166
2) Kleeff, J., Korc, M., Apte, M. et al. Pancreatic
cancer. Nat Rev Dis Primers 2, 16022 (2016).
https://doi.org/10.1038/nrdp.2016.22
3) Tzeng, Ching-Wei D et al. “Serum carbohydrate
antigen 19-9 represents a marker of response to
neoadjuvant therapy in patients with borderline
resectable pancreatic cancer.” HPB : the official
journal of the International Hepato Pancreato
Biliary Association vol. 16,5 (2014): 430-8.
doi:10.1111/hpb.12154
4) Lee W, Park Y, Kwon JW, et al. Reduced and
Normalized Carbohydrate Antigen 19-9
Concentrations after Neoadjuvant Chemotherapy
Have Comparable Prognostic Performance in
Patients with Borderline Resectable and Locally
Advanced Pancreatic Cancer. J Clin Med 2020;
9(5).
5) De La Cruz, Maria Syl D et al. “Diagnosis and
management of pancreatic cancer.” American
family physician vol. 89,8 (2014): 626-32.
6) Tsai, Susan et al. “Importance of Normalization
of CA19-9 Levels Following Neoadjuvant Therapy
in Patients With Localized Pancreatic Cancer.”
Annals of surgery vol. 271,4 (2020): 740-747.
doi:10.1097/SLA.0000000000003049

